[1]

[2]

SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.

[3]

LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.

[4]

YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.

[5]

XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.

[6]

CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.

[7]

. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.

[8]

. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.

[9]

[10]

YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.

[11]

DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.

[12]

GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.

[13]

. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.

[14]

. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.

[15]

. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

组别	例数	Hb(g/L)	RBC(×10¹²/L)	HCT	PLT(×10⁹/L)
不良反应组
输血前	10	49±13	2.57±0.56	0.25±0.06	47±5
输血后	10	81±8	3.72±0.65	0.33±0.06	102±13
无不良反应组
输血前	146	52±15	2.62±0.58	0.27±0.07	49±6
输血后	146	87±9	4.20±0.68	0.37±0.07	132±18

组别	例数	Hb(g/L)	RBC(×10¹²/L)	HCT	PLT(×10⁹/L)
不良反应组
输血前	10	49±13	2.57±0.56	0.25±0.06	47±5
输血后	10	81±8	3.72±0.65	0.33±0.06	102±13
无不良反应组
输血前	146	52±15	2.62±0.58	0.27±0.07	49±6
输血后	146	87±9	4.20±0.68	0.37±0.07	132±18

组别	例数	PT(s)	APTT(s)	TT(s)	FiB(g/L)
不良反应组
输血前	10	16.5±2.37	36.5±4.1	20.1±3.0	1.1±0.1
输血后	10	20.5±2.7^#	42.5±4.4^#	30.1±1.7^#	2.1±0.5^#
无不良反应组
输血前	146	16.3±2.25	36.4±4.0	20.8±3.1	1.1±0.1
输血后	146	13.3±2.7^*	28.4±3.7^*	17.3±1.4^*	4.0±0.7^*

组别	例数	PT(s)	APTT(s)	TT(s)	FiB(g/L)
不良反应组
输血前	10	16.5±2.37	36.5±4.1	20.1±3.0	1.1±0.1
输血后	10	20.5±2.7^#	42.5±4.4^#	30.1±1.7^#	2.1±0.5^#
无不良反应组
输血前	146	16.3±2.25	36.4±4.0	20.8±3.1	1.1±0.1
输血后	146	13.3±2.7^*	28.4±3.7^*	17.3±1.4^*	4.0±0.7^*

RichHTML

PDF (PC)

[1]	郭兑山, 王德智. 异位妊娠与自身输血[J]. 中国实用妇科与产科杂志, 2000,16(4):210-211.
[2]	赵绥民, 田兆嵩. 急性失血病人的成分输血[J]. 中国输血杂志, 1999,12(1):46-47.
[3]	何静, 熊鸿燕. 创伤输血的研究进展[J]. 中华创伤杂志, 2006,22(4):316-318.
[4]	SPINELLA PC.Warm fresh whole blood transfusion for severe hemorrhage: U.S. military and potential civilian applications[J].Crit Care Med, 2008,36(7 Suppl):S340-S345.
[5]	MYNSTER T, CHRISTENSEN IJ, MOESGAARD F, et al.Effects of the combination of blood transfusion and postoperative infectious complications on prognosis after surgery for colorectal cancer. Danish RANX05 Colorectal Cancer Study Group[J]. Br J Surg, 2000,87(11):1553-1562.